TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02508792

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LASER PLACEBO
Description: The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
Study: NCT02437708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem and progenitor cells
Study: NCT03578952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with Evolut R valve
Description: TAVR with Evolut R valve
Study: NCT03445169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan Tablets
Study: NCT02975596

Intervention type: OTHER
Group type: OTHER
Intervention: Awareness
Description: Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.

Intervention type: OTHER
Group type: OTHER
Intervention: Awareness
Description: Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.

Intervention type: OTHER
Group type: OTHER
Intervention: Awareness
Description: Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
Study: NCT00636766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study: NCT02975596

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
Study: NCT00636766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study: NCT00928551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vabicaserin
Study: NCT02089399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevikar(amlodipne/olmesartan)
Description: Treatment AB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crestor(Rosuvastatin)
Description: Treatment AB/Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crestor(Rosuvastatin)
Description: Treatment AB/Treatment C
Study: NCT02690870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
Study: NCT02975596

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
Study: NCT01585506

Intervention type: OTHER
Intervention: No treatment given
Description: Patients to complete the WHO-5 Well-being Index questionnaire
Study: NCT02975596

Intervention type: OTHER
Group type: OTHER
Intervention: Empowerment
Description: Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines.

Intervention type: OTHER
Group type: OTHER
Intervention: Empowerment
Description: Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines.

Intervention type: OTHER
Group type: OTHER
Intervention: Accessibility
Description: Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
Study: NCT01585506

Intervention type: OTHER
Intervention: No treatment given
Description: Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues
Study: NCT00194532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Description: Cefpodoxime 100mg twice a day(BID)for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 250mg twice a day (BID)for 3 days
Study: NCT02975596

Intervention type: OTHER
Group type: OTHER
Intervention: Accessibility
Description: Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.

Intervention type: OTHER
Group type: OTHER
Intervention: Accessibility
Description: Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
Study: NCT02934503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
Study: NCT00272402

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Intervention
Description: Intervention consists of simulated case based learning for physicians.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Office System Redesign Intervention
Description: Intervention consists of clinical decision support within the electronic medical record.
Study: NCT02934503

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
Study: NCT01669239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
Study: NCT03851289

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin and calcium sulfate

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich fibrin and xenograft
Study: NCT04252729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy sessions based on Psychoanalytic Psychosomatics
Study: NCT06064448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
Study: NCT00925015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 10 mg/kg
Description: Dalotuzumab at 10 mg/kg was intravenously administered once weekly
Study: NCT02054104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 cell lysates
Description: H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
Study: NCT06064448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningbitai capsule + sildenafil
Description: The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
Study: NCT00925015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 10 mg/kg
Description: Dalotuzumab at 10 mg/kg was intravenously administered once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
Study: NCT00925015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 15/7.5 mg/kg
Description: Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
Study: NCT02054104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iscomatrix adjuvant
Description: H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
Study: NCT00975156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Conventional physical therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Robotic-assisted walking device
Study: NCT02375230

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR SOPA
Description: Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift.
Study: NCT02054104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iscomatrix adjuvant
Description: H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
Study: NCT03548181

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Autonomous Physiotherapist Agent (VAPA)
Description: A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
Study: NCT00933075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
Study: NCT02531581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 9% isotonic
Description: normal saline 500 cc / 4 hours and 1 L / 24 hours
Study: NCT03958227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Therapy plus Exercise Intervention
Description: Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
Study: NCT04546477

Intervention type: DEVICE
Group type: OTHER
Intervention: Stent implantation
Description: Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon.
Study: NCT01972048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mMammogram
Description: Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Print brochure
Description: Mailed print brochure about breast cancer screening and community resources.
Study: NCT00475683

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mouth wash
Description: Mouth wash with chlorehexidin, three times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumol
Description: 5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
Study: NCT03548181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Autonomous Physiotherapist Agent (VAPA)
Description: A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
Study: NCT03709654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB01
Description: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
Study: NCT01166022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
Study: NCT00766532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Any aromatase inhibitor started as initial adjuvant therapy
Study: NCT03672019

Intervention type: BEHAVIORAL
Intervention: FACT-Hep
Description: Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
Study: NCT03241914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: At a dosage of 160 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: At a dosage of 160 mg/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing Intrauterine System(LNG-IUS)
Description: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
Study: NCT03951623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-523
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-523
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.